Edition:
India

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

2.35USD
19 Jul 2019
Change (% chg)

$0.02 (+0.86%)
Prev Close
$2.33
Open
$2.41
Day's High
$2.53
Day's Low
$2.31
Volume
258,486
Avg. Vol
132,749
52-wk High
$36.25
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Altimmune To Acquire Spitfire Pharma
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Altimmune Inc ::ALTIMMUNE SIGNS DEFINITIVE AGREEMENT TO ACQUIRE SPITFIRE PHARMA, INC. ADDING NASH DRUG CANDIDATE TO PORTFOLIO.ALTIMMUNE INC - SPITFIRE SHAREHOLDERS WILL RECEIVE AN UPFRONT PAYMENT OF $5 MILLION IN ALTIMMUNE COMMON STOCK.ALTIMMUNE INC - ALTIMMUNE PLANS TO ADVANCE DRUG CANDIDATE INTO CLINIC DURING 2020.ALTIMMUNE INC - SPITFIRE SHAREHOLDERS WILL BE ELIGIBLE TO RECEIVE AN ADDITIONAL $8 MILLION IN FUTURE REGULATORY AND CLINICAL MILESTONES.ALTIMMUNE INC - SPITFIRE SHAREHOLDERS ARE ALSO ELIGIBLE TO RECEIVE UP TO $80 MILLION IN SALES-BASED MILESTONES..ALTIMMUNE INC - TO RECEIVE RIGHTS TO NOVEL GLP-1/GLUCAGON DUAL AGONIST THAT ADDRESSES OBESITY AND METABOLIC DYSFUNCTION.  Full Article

Altimmune Announces Successful Pre-Ind Meeting With FDA
Monday, 10 Jun 2019 

June 10 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES SUCCESSFUL PRE-IND MEETING WITH FDA.ALTIMMUNE INC - FDA DID NOT OBJECT TO PLANNED STUDY DESIGN AND PATIENT POPULATIONS.ALTIMMUNE INC - FDA DID NOT NOT RECOMMEND ANY ADDITIONAL STUDIES IN PREPARATION FOR AN IND SUBMISSION AND INITIATION OF PHASE 2 TRIALS.ALTIMMUNE INC - INTENDS TO CONDUCT A PHASE 2 STUDY IN UNITED STATES.ALTIMMUNE INC - PHASE 2 TRIAL IS ANTICIPATED TO START IN 2020..  Full Article

Altimmune Files For Mixed Shelf Of Upto $250 Mln
Friday, 5 Apr 2019 

April 4 (Reuters) - Altimmune Inc ::ALTIMMUNE INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.  Full Article

Altimmune Announces Financial Results For Year Ended Dec 31
Tuesday, 2 Apr 2019 

April 1 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2018 AND PROVIDES CORPORATE UPDATE.  Full Article

Altimmune says Cash, Cash Equivalents And Restricted Cash As Of Dec. 31 Is $34.4 Mln
Friday, 8 Mar 2019 

March 8 (Reuters) - Altimmune Inc ::ALTIMMUNE INC - PRELIMINARY NET LOSS PER SHARE FOR THE YEAR ENDED DECEMBER 31, 2018, $14.87 TO $15.23.ALTIMMUNE INC - PRELIMINARY REVENUE FOR THE YEAR ENDED DEC 31, 2018 $10 –10.5 MILLION.ALTIMMUNE INC - CASH, CASH EQUIVALENTS AND RESTRICTED CASH AS OF DECEMBER 31, 2018 IS $34.4 MILLION.  Full Article

Altimmune Announces Clinical Program Updates And Plans For Pipeline Expansion
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES CLINICAL PROGRAM UPDATES AND PLANS FOR PIPELINE EXPANSION.ALTIMMUNE INC - ADVANCING MANUFACTURE OF A MULTIVALENT FORMULATION AND INTENDS TO INITIATE ADDITIONAL PHASE 2 STUDIES ONCE MANUFACTURING IS COMPLETE.ALTIMMUNE - CONDUCTING EXTENSION STUDY FOR PREVIOUS PHASE 2A STUDY PARTICIPANTS TO GAUGE FURTHER DURABILITY OF HAI RESPONSES A YEAR AFTER VACCINATION.ALTIMMUNE INC - WILL BE EVALUATING OTHER CLINICAL MEASURES OF NASOVAX IMMUNOGENICITY.ALTIMMUNE INC - INTENDS TO PURSUE ADDITIONAL COMPLEMENTARY INDICATIONS FOR ITS DIFFERENTIATED SYNTHETIC IMMUNOTHERAPEUTIC PEPTIDE TECHNOLOGY.ALTIMMUNE INC - CO PLANS TO EXPLORE OPPORTUNITIES TO EITHER ACQUIRE PRODUCTS OR PARTNER IN NOVEL IMMUNOTHERAPY INDICATIONS TO FURTHER EXPAND PIPELINE.ALTIMMUNE INC - PLANS TO ADVANCE HBV-SPECIFIC IMMUNE ACTIVATION BY HEPTCELL INTO PHASE 2 DEVELOPMENT.  Full Article

Altimmune Says William Enright To Resign As President, CEO Of Co And Member Of Board
Tuesday, 23 Oct 2018 

Oct 22 (Reuters) - Altimmune Inc ::ALTIMMUNE SAYS ON OCT 16 WILLIAM ENRIGHT NOTIFIED BOARD THAT HE INTENDS TO RESIGN AS PRESIDENT, CEO OF CO AND MEMBER OF BOARD - SEC FILING.ALTIMMUNE SAYS ENRIGHT STATED THAT HIS DECISION TO RESIGN INVOLVED A DISAGREEMENT OVER SCOPE OF HIS RESPONSIBILITIES AT CO.ALTIMMUNE INC - CO, ENRIGHT HAVE AGREED THAT ENRIGHT WILL REMAIN PRESIDENT, CEO UNTIL EARLIER OF APPOINTMENT OF HIS SUCCESSOR OR FEB 28, 2019.ALTIMMUNE INC - ENRIGHT WILL ALSO REMAIN ON BOARD UNTIL HIS RESIGNATION AS PRESIDENT AND CEO IS EFFECTIVE.ALTIMMUNE - ENRIGHT'S DECISION TO RESIGN IS NOT OTHERWISE RESULT OF ANY DISAGREEMENT ON ANY MATTERS RELATING TO CO'S OPERATIONS, POLICIES/PRACTICES.ALTIMMUNE INC - BOARD HAS BEGUN A PROCESS TO IDENTIFY ENRIGHT'S SUCCESSOR.  Full Article

Altimmune Announces $4.9 Mln Registered Direct Offering
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK.ALTIMMUNE INC - REGISTERED DIRECT OFFERING OF 286,633 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $17.02 PER SHARE.ALTIMMUNE INC - TO USE NET PROCEEDS FROM THIS OFFERING FOR CONTINUED ADVANCEMENT OF DEVELOPMENT ACTIVITIES FOR OUR CLINICAL-STAGE PRODUCT PIPELINE.  Full Article

Altimmune Announces Additional Positive Data From Its Phase 2A Study Of NasoVAX Intranasal Influenza Vaccine
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES ADDITIONAL POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE.ALTIMMUNE INC - DURABLE SERUM IMMUNE RESPONSE AT SIX MONTHS COMPARED TO OVER 50% DECLINE WITH FLUZONE.ALTIMMUNE - SIX-MONTH DATA DEMONSTRATES STATISTICALLY SUPERIOR MUCOSAL IMMUNE RESPONSE PROVIDING A FIRST LINE OF DEFENSE AGAINST INFECTION.ALTIMMUNE INC - SIX-MONTH DATA DEMONSTRATES CONTINUED CLEAN SAFETY PROFILE.  Full Article

Altimmune Reports Q2 Loss Per Share Of $0.34
Wednesday, 15 Aug 2018 

Aug 14 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.34.Q2 REVENUE $2.4 MILLION VERSUS $3.0 MILLION.AT JUNE 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $4.8 MILLION.DURING QUARTER, COMPANY RECEIVED $4.0 MILLION IN CASH RELATED TO ITS FEDERAL TAX REFUND RECEIVABLE.  Full Article